Systemic symptoms predict presence or development of severe sepsis and septic shock

Infectious Diseases

Volumn 48, Issue 3, 2016, Pages 209-214

  Edman Wallér, Jon ^a   Ljungström, Lars ^b   Jacobsson, Gunnar ^b   Andersson, Rune ^c   Werner, Maria ^a  

^a Department of Infectious Diseases   (Sweden)

^b SKARABORG HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Altered mental status; Dyspnea; Gastrointestinal symptoms; Muscle weakness; Sepsis; Septic shock; Severe sepsis; Symptoms

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHILL; COMMUNITY ACQUIRED INFECTION; DISEASE SEVERITY; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MUSCLE WEAKNESS; PAIN; RETROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SWEDEN; SYMPTOMATOLOGY; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; HOSPITAL ADMISSION; MICROBIOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; ODDS RATIO; SHOCK, SEPTIC; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DYSPNEA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; ODDS RATIO; PATIENT ADMISSION; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; STATISTICS, NONPARAMETRIC; SWEDEN; YOUNG ADULT;

EID: 84962259974     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1104719     Document Type: Article

References (31)

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. ACCP/SCCM. Chest. 1992;101:1644-1655.
2. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167-1174.
3. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-1596.
4. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749-1755.
5. Daniels R. Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective). J Antimicrob Chemother. 2011; 66(Suppl 2):ii11-ii23.
6. Carlbom DJ, Rubenfeld GD. Barriers to implementing protocol-based sepsis resuscitation in the emergency department-results of a national survey. Crit Care Med. 2007;35:2525-2532.
7. Callahan LA, Supinski GS. Sepsis-induced myopathy. Crit Care Med. 2009;37(Suppl 10):S354-S367.
8. Aare S, Radell P, Eriksson LI, et al. Role of sepsis in the development of limb muscle weakness in a porcine intensive care unit model. Physiol genomics. 2012;44:865-877.
9. Eikermann M, Koch G, Gerwig M, et al. Muscle force and fatigue in patients with sepsis and multiorgan failure. Intensive Care Med. 2006;32:251-259.
10. Gofton TE, Young GB. Sepsis-associated encephalopathy. Nat Rev Neurol. 2012;8:557-566.
11. Martin BJ, Buth KJ, Arora RC, Baskett RJ. Delirium as a predictor of sepsis in post-coronary artery bypass grafting patients: a retrospective cohort study. Crit Care. 2010;14:R171.
12. Taniguchi T, Tsuha S, Takayama Y, Shiiki S. Shaking chills and high body temperature predict bacteremia especially among elderly patients. Springerplus. 2013;2:624.
13. Ekelund K, Lemcke A, Konradsen HB. Evaluation of gastrointestinal symptoms as primary sign of severe invasive group A streptococcal infections. Ind J Med Res. 2004;119(Suppl):179-182.
14. Brink M, Cronqvist J, Furebring M, et al. 2013. Svår sepsis och septisk chock-tidig identifiering och initial handläggning. Sweden: Svenska Infektionsläkarfö reningen/Swedish Society for Infectious Diseases.
15. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.
16. Kenzaka T, Okayama M, Kuroki S, et al. Importance of vital signs to the early diagnosis and severity of sepsis: association between vital signs and sequential organ failure assessment score in patients with sepsis. Intern Med. 2012;51:871-876.
17. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.
18. Wester AL, Dunlop O, Melby KK, et al. Age-related differences in symptoms, diagnosis and prognosis of bacteremia. BMC Infect Dis. 2013;13:346.
19. Studnek JR, Artho MR, Garner CL, Jones AE. The impact of emergency medical services on the ED care of severe sepsis. Am J Emerg Med. 2012;30:51-56.
20. Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003;31:2332-2338.
21. van Gestel A, Bakker J, Veraart CP, van Hout BA. Prevalence and incidence of severe sepsis in Dutch intensive care units. Crit Care. 2004;8:R153-R162.
22. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-382.
23. Bauer TT, Ewig S, Marre R, et al.; The Capnetz Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260:93-101.
24. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
25. Sakr Y, Elia C, Mascia L, et al. The influence of gender on the epidemiology of and outcome from severe sepsis. Crit Care. 2013;17:R50.
26. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 2000;26(Suppl 2): S148-S152.
27. Strehlow MC, Emond SD, Shapiro NI, et al. National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med. 2006;48:326-31, 31.e1-e3.
28. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247.
29. Henriksen DP, Laursen CB, Jensen TG, et al. Incidence rate of community-acquired sepsis among hospitalized acute medical patients-a population-based survey. Crit Care Med. 2015;43:13-21.
30. Storgaard M, Hallas J, Gahrn-Hansen B, et al. Short-and long-term mortality in patients with community-acquired severe sepsis and septic shock. Scand J Infect Dis. 2013;45:577-583.
31. Henriksen DP, Pottegard A, Laursen CB, et al. Risk factors for hospitalization due to community-acquired sepsis-a population-based case-control study. PLoS One. 2015;10:e0124838.